Oral Antibiotics for Skin Inflammation
For uncomplicated nonpurulent cellulitis, use a β-lactam antibiotic (cephalexin, dicloxacillin, or amoxicillin) targeting streptococci for 5-6 days; add MRSA coverage only if the patient fails to respond to initial therapy or has systemic toxicity.
Treatment Algorithm for Outpatient Cellulitis
Step 1: Classify the Infection Type
Nonpurulent cellulitis (no drainage, no abscess):
- Diffuse erythema, warmth, swelling
- No purulent drainage or exudate
- Primary pathogen: β-hemolytic streptococci 1
Purulent cellulitis (drainage present, no drainable abscess):
- Cellulitis with purulent drainage or exudate
- Primary pathogen: Community-acquired MRSA 1
Step 2: Select Initial Antibiotic Based on Infection Type
For Nonpurulent Cellulitis (Most Common):
First-line therapy (targeting streptococci):
- Cephalexin 500 mg four times daily 2
- Dicloxacillin 500 mg four times daily 2
- Amoxicillin (as part of combination if needed) 1
Duration: 5-6 days 3
The 2021 American College of Physicians guidelines specifically recommend 5-6 days for patients who can self-monitor with close follow-up 3. The IDSA guidelines note that treatment should extend beyond 5 days only if infection has not improved 1.
For Purulent Cellulitis:
Empirical MRSA coverage required 1:
- Clindamycin 300-450 mg three times daily (covers both streptococci and MRSA) 1
- TMP-SMX 1-2 double-strength tablets twice daily PLUS a β-lactam (e.g., amoxicillin) for streptococcal coverage 1
- Doxycycline or minocycline 100 mg twice daily PLUS a β-lactam 1
- Linezolid 600 mg twice daily (covers both, but expensive) 1
Duration: 5-10 days based on clinical response 1
Step 3: When to Add MRSA Coverage for Nonpurulent Cellulitis
Add MRSA-active antibiotics if:
- No clinical response after 48-72 hours of β-lactam therapy 1
- Systemic toxicity present (fever >38.5°C, tachycardia >110 bpm) 1
- High-risk features: penetrating trauma, known MRSA colonization, injection drug use, or SIRS 3
Critical Evidence Points
The IDSA guidelines explicitly state that for nonpurulent cellulitis, "the role of CA-MRSA is unknown" and empirical streptococcal coverage is the standard 1, 4. This is supported by:
- A 2013 randomized controlled trial found no benefit from adding TMP-SMX to cephalexin for uncomplicated cellulitis (85% cure rate with combination vs 82% with cephalexin alone, p=0.66) 5
- Research suggests streptococci cause the vast majority of nonpurulent cellulitis cases 6
- Cost-effectiveness analyses show cephalexin remains optimal at current MRSA prevalence levels 7
Common Pitfalls to Avoid
Over-prescribing MRSA coverage: Do not empirically cover MRSA in nonpurulent cellulitis without risk factors or treatment failure 1, 5
Using TMP-SMX alone: This lacks streptococcal coverage and should not be used as monotherapy for nonpurulent cellulitis 1
Excessive treatment duration: Recent evidence supports 5-6 days for uncomplicated cases, not the traditional 10-14 days 3
Ignoring local resistance patterns: Check clindamycin resistance rates in your area; if >10%, consider alternative MRSA agents 1
Using rifampin: Never use as monotherapy or adjunctive therapy for skin infections 1, 4